Chemical Structure (Xer00 0002 01)
Xermelo Tablet
Product Images NDC 70720-125
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Xermelo (NDC 70720-125). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Tersera Therapeutics Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Xer00 0002 02)
Principal Display Panel (3x7 weekly pack)
XERMELO tablets contain 250 mg of telotristat ethyl and come in a weekly pack with 21 tablets. The active ingredient is produced in China and the tablets are manufactured in the USA by TerSera Therapeutics LLC. They are only for oral use and should be stored at room temperature. Dosage and administration information is available in the package insert. This medication should be kept out of reach of children. The NDC number for this medication is 70720-125-22.*
Principal Display Panel (28 Day Case Label)
XERMELO is a medication available in tablet form and containing telotristat ethyl. The medication is indicated for the treatment of Carcinoid Syndrome Diarrhea (CSD) in combination with SSA (somatostatin analog) therapy in adults inadequately controlled by SSA therapy alone.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
